Posted inNephrology news Rheumatology
Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial
This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

